Is There A LIfe for DES After Discontinuation of Clopidogrel:The ITALIC PLUS Trial
试验速览
- 阶段
- 不适用
- 入组人数
- 1,240
- 试验地点
- 1
- 主要终点
- composite endpoint:death, myocardial infarction, repeat angioplasty due to the occurrence of restenosis, occurrence of stroke and major bleeding
研究概览
简要总结
The ITALIC PLUS Trial was designed with the objective of extending to other countries the enrollment of patients into the ITALIC trial initially conducted in France, in order to achieve statistical significance by pooling the data of both trials.
详细描述
The use of drug-eluting stents has resulted in a significant reduction in the restenosis rate and in the need for repeat angioplasty of the stented lesion. However, the occurrence of late stent thrombosis has resulted in an increase in the duration of dual antiplatelet treatment.
According to the guidelines of the ESC, the current recommended duration of dual antiplatelet treatment is 12 months.
A relationship has been demonstrated between the occurrence of late stent thrombosis and aspirin resistance.
Furthermore, dual anti-platelet treatment is associated with an increase in bleeding, the severity of which has been well documented. In addition, the patients involved, and especially those over 70, have significant co-morbidities often requiring extra-cardiac surgery which cannot easily be carried out in patients on dual antiplatelet treatment or clopidogrel.
The objective of this study is to determine whether, after a period of 6 months following Drug eluting stent (DES) implantation in patients regarded as sensitive to aspirin, dual antiplatelet therapy may be replaced by aspirin alone.
研究设计
- 研究类型
- Observational
- 观察模型
- Cohort
- 时间视角
- Prospective
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Male or female subject ≥ 18 years of age eligible for PCI with at least one drug eluting stent (name: Xience) implanted in all clinical situations excluding primary PCI for acute MI and treatment of the left main artery.
- •Male or female subject ≥ 18 years of age eligible for PCI with at least one DES Xience.
- •Patient not pre-treated with protein IIb/IIIa inhibitors (name: abxicimab or eptifibatide) during hospitalization
- •Patient pre-treated with aspirin and clopidogrel before PCI
- •ASA check at least 24 hours after the interruption of tirofiban
- •The subject has given written informed and dated consent to participate in this study.
排除标准
- •Subjects not able to give informed consent
- •Prior implantation of DES
- •Known platelets < 100 000/µl or known hemorrhagic diathesis
- •Oral anticoagulation or treatment with abxicimab or eptifibatide during hospitalization
- •ASA check less than 24 hours after the interruption of tirofiban
- •Thrombolytic therapy within 4 days before ASA check
- •Contra-indication to aspirin or clopidogrel
- •Recent major surgery < 6 weeks
- •Evidence of an active gastrointestinal or urogenital bleeding
- •Severe liver insufficiency
- •Primary PCI for acute MI
- •Left main PCI
- •Any scheduled surgery during the year after enrollment
- •Severe concomitant disease with life expectation < two years
结局指标
主要结局
composite endpoint:death, myocardial infarction, repeat angioplasty due to the occurrence of restenosis, occurrence of stroke and major bleeding
时间窗: one year
次要结局
- composite endpoint:Death, myocardial infarction, repeat angioplasty due to the occurrence of restenosis, occurrence of stroke and major bleeding and minor bleeding(36-month period)